Italia markets close in 19 minutes

FTSE MIB
34.588,86
-236,15(-0,68%)
Dow Jones
39.840,31
+33,54(+0,08%)
Nasdaq
16.794,70
-0,17(-0,00%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
79,21
-0,59(-0,74%)
Bitcoin EUR
64.673,81
+3.023,50(+4,90%)

NVCR Jun 2024 15.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,0800

0,0000

(0,00%)

In data: 02:23PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in